ADAG Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers...

Stats
Today's Volume	8 398.00
Average Volume	33 276.00
Market Cap	112.50M
EPS	$0 ( 2024-04-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.80
ATR14	$0.0560 (2.20%)

Volume Correlation

Long: -0.06 (neutral)

Short: 0.05 (neutral)

Signal:(54.625) Neutral

Adagene Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Adagene Inc. Correlation - Currency/Commodity

0.03
( neutral )

-0.35
( neutral )

0.00
( neutral )

-0.46
( neutral )

-0.08
( neutral )

Adagene Inc. Financials

Annual	2023
Revenue:	$18.11M
Gross Profit:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2023
Revenue:	$18.11M
Gross Profit:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2022
Revenue:	$9.29M
Gross Profit:	$9.29M (100.00 %)
EPS:	$-1.850

FY	2021
Revenue:	$10.18M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.825

Financial Reports:

No articles found.

Adagene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Adagene Inc.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.